X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5048) 5048
Book Review (813) 813
Publication (544) 544
Newsletter (18) 18
Book Chapter (12) 12
Conference Proceeding (9) 9
Dissertation (3) 3
Magazine Article (3) 3
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4733) 4733
animals (3014) 3014
humans (2823) 2823
mice (2495) 2495
female (1920) 1920
immunology (1891) 1891
interleukin-12 (1422) 1422
male (1355) 1355
cytokines (1018) 1018
dendritic cells (940) 940
mice, inbred balb c (887) 887
mice, inbred c57bl (869) 869
interleukin-12 - metabolism (824) 824
interleukin-12 - immunology (817) 817
interleukin-12 - genetics (790) 790
il-12 (778) 778
immunotherapy (757) 757
t-cells (694) 694
adult (691) 691
medicine, research & experimental (681) 681
oncology (666) 666
in-vivo (637) 637
interleukin-12 - therapeutic use (636) 636
middle aged (621) 621
expression (607) 607
dendritic cells - immunology (591) 591
cancer (584) 584
cells, cultured (580) 580
interferon-gamma (578) 578
interleukin-12 - biosynthesis (567) 567
ifn-gamma (532) 532
pharmacology & pharmacy (492) 492
inflammation (461) 461
lymphocytes (455) 455
interleukin-12/23 monoclonal-antibody (451) 451
health aspects (447) 447
cytokine (445) 445
double-blind (441) 441
t cells (440) 440
abridged index medicus (433) 433
disease models, animal (424) 424
psoriasis (423) 423
research (414) 414
th1 cells - immunology (414) 414
analysis (407) 407
cell biology (398) 398
interleukins (390) 390
interleukin 12 (385) 385
cells (377) 377
activation (374) 374
t-lymphocytes - immunology (368) 368
interferon-gamma - biosynthesis (366) 366
care and treatment (364) 364
cell line, tumor (362) 362
dermatology (358) 358
immunity (357) 357
interferon-gamma - metabolism (353) 353
antibodies, monoclonal - therapeutic use (339) 339
macrophages (327) 327
biochemistry & molecular biology (326) 326
immune response (325) 325
treatment outcome (324) 324
aged (321) 321
biotechnology & applied microbiology (321) 321
gene expression (313) 313
psoriasis - drug therapy (311) 311
enzyme-linked immunosorbent assay (309) 309
interleukin-12 - blood (304) 304
interleukin-12 - pharmacology (304) 304
flow cytometry (300) 300
therapy (298) 298
induction (297) 297
vaccination (293) 293
interferon-gamma - immunology (292) 292
tumors (288) 288
research article (286) 286
ustekinumab (285) 285
killer cells, natural - immunology (283) 283
mice, knockout (278) 278
antigens (277) 277
immune system (277) 277
time factors (277) 277
gene therapy (276) 276
article (272) 272
immune-responses (266) 266
vaccines (266) 266
medicine (263) 263
responses (259) 259
infection (256) 256
proteins (249) 249
rodents (249) 249
in-vitro (247) 247
tumor-necrosis-factor (244) 244
dendritic cells - drug effects (241) 241
cd8-positive t-lymphocytes - immunology (239) 239
dendritic cells - metabolism (238) 238
genetics & heredity (235) 235
cytokines - biosynthesis (233) 233
cytokines - metabolism (230) 230
interleukin-12 - administration & dosage (229) 229
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4955) 4955
Chinese (48) 48
Japanese (26) 26
Spanish (10) 10
Polish (8) 8
German (7) 7
French (5) 5
Russian (4) 4
Turkish (3) 3
Portuguese (2) 2
Danish (1) 1
Finnish (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2014, Volume 73, Issue 6, pp. 990 - 999
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9993, pp. 552 - 561
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2010, Volume 362, Issue 2, pp. 118 - 128
In this 12-week randomized trial comparing two biologic agents known to be effective for psoriasis, ustekinumab (an interleukin-12 and interleukin-23 blocker)... 
RANDOMIZED-CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | PLACEBO | CHRONIC PLAQUE PSORIASIS | EFFICACY | SAFETY | DOUBLE-BLIND | METHOTREXATE | TNF INHIBITION | INDUCTION | INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY | Severity of Illness Index | Psoriasis - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunologic Factors - administration & dosage | Immunoglobulin G - therapeutic use | Ustekinumab | Antibodies, Monoclonal - therapeutic use | Male | Receptors, Tumor Necrosis Factor - administration & dosage | Immunoglobulin G - administration & dosage | Receptors, Tumor Necrosis Factor - therapeutic use | Antibodies, Monoclonal, Humanized | Etanercept | Antibodies, Monoclonal - administration & dosage | Interleukin-23 - antagonists & inhibitors | Interleukin-12 - antagonists & inhibitors | Adult | Female | Immunosuppressive Agents - administration & dosage | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Immunologic Factors - therapeutic use | Dosage and administration | Psoriasis | Comparative analysis | Drug therapy | Fees & charges | Cytokines | Stock options | Laboratories | Research & development--R&D | Equity | Interleukin 23 | Interleukin 12 | Tumor necrosis factor-α | Light therapy | Patients | Studies | Tumor necrosis factor-TNF | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 05/2008, Volume 58, Issue 5, pp. 826 - 850
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 76, Issue 4, pp. 662 - 669.e1
Background Drug survival is defined as the time period of treatment with a certain drug until its cessation. The role of previous exposure to traditional... 
Dermatology | ustekinumab | etanercept | infliximab | psoriasis | biologic medications | drug survival | adalimumab | ADHERENCE | DISCONTINUATION | DERMATOLOGY | RATES | IMMUNOGENICITY | INTERVENTIONS | CONSEQUENCES | AGENTS | VULGARIS | REGISTRY | Etanercept - administration & dosage | Dermatologic Agents - administration & dosage | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Dermatologic Agents - therapeutic use | Methotrexate - therapeutic use | Infliximab - therapeutic use | Infliximab - administration & dosage | Psoriasis - complications | Time Factors | Adult | Female | Acitretin - therapeutic use | Drug Therapy, Combination | Ustekinumab - administration & dosage | Immunosuppressive Agents - administration & dosage | Interleukin-12 Receptor beta 1 Subunit - antagonists & inhibitors | Databases, Factual | Psoriasis - drug therapy | Drug Tolerance | Ustekinumab - therapeutic use | Metabolic Syndrome - complications | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Israel | Drug Substitution | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Etanercept - therapeutic use | Psoriasis | Patient outcomes | Formulae, receipts, prescriptions | Medical care | Family medicine | Dermatologic agents | Drug therapy | Quality management | Beer | Analysis | Retinoids | Index Medicus
Journal Article
Science, ISSN 0036-8075, 01/2018, Volume 359, Issue 6371, pp. 91 - 97
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that... 
CELL LUNG-CANCER | MELANOMA | MICROENVIRONMENT | INTESTINAL MICROBIOTA | CYCLOPHOSPHAMIDE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | GENES | RESISTANCE | ANTITUMOR IMMUNITY | NIVOLUMAB | CD4 Antigens - immunology | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Microbiome - genetics | Fecal Microbiota Transplantation | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Metagenome - genetics | Neoplasms - therapy | Animals | Receptors, CCR - immunology | Interleukin-12 - immunology | Receptors, CXCR3 - immunology | T-Lymphocytes - immunology | Mice | Gastrointestinal Microbiome - immunology | Verrucomicrobia - genetics | Verrucomicrobia - immunology | Care and treatment | Cell receptors | Microbiota (Symbiotic organisms) | Immunotherapy | Epithelial tumors | Physiological aspects | Health aspects | Methods | Apoptosis | PD-1 protein | Lung | Interleukin | Microbiomes | Transplantation | Lymphocytes T | Anticancer properties | Microbiota | Lymphocytes | Bacteria | Feces | Supplementation | Gnotobiotics | Kidneys | Melanoma | Dietary supplements | Interleukin 12 | Abundance | CXCR3 protein | Patients | CD4 antigen | Immune checkpoint | Antibiotics | Flora | PD-L1 protein | Relative abundance | Antitumor activity | CCR9 protein | Tumors | Kidney transplantation | Cancer | Index Medicus | Life Sciences
Journal Article
JAMA, ISSN 0098-7484, 08/2011, Volume 306, Issue 8, pp. 864 - 871
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1551 - 1560
Journal Article
Journal Article